Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage

BACKGROUND: Lenvatinib is an oral inhibitor of multiple receptor tyrosine kinases (RTKs) targeting vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet growth factor receptor α (PDGFR α), RET and KIT. Antiangiogenesis activity of lenvatinib in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Yuji, Matsui, Junji, Matsushima, Tomohiro, Obaishi, Hiroshi, Miyazaki, Kazuki, Nakamura, Katsuji, Tohyama, Osamu, Semba, Taro, Yamaguchi, Atsumi, Hoshi, Sachi Suzuki, Mimura, Fusayo, Haneda, Toru, Fukuda, Yoshio, Kamata, Jun-ichi, Takahashi, Keiko, Matsukura, Masayuki, Wakabayashi, Toshiaki, Asada, Makoto, Nomoto, Ken-ichi, Watanabe, Tatsuo, Dezso, Zoltan, Yoshimatsu, Kentaro, Funahashi, Yasuhiro, Tsuruoka, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156793/
https://www.ncbi.nlm.nih.gov/pubmed/25197551
http://dx.doi.org/10.1186/2045-824X-6-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156793/
https://www.ncbi.nlm.nih.gov/pubmed/25197551
http://dx.doi.org/10.1186/2045-824X-6-18

Ejemplares similares